ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

duvakitug

Also written as “Duvakitug”, “TEV-48574” and “TEV-48574 Dose Regimen A”.

In Sanofi’s pipeline, TL1A mAb. Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Hidradenitis · Asthma, led by 2 companies.

Drug pageDuvakitug: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 15, 20259 company-led studies, 7 open or runningCo-development: Teva and Sanofi, Oct 2023Next primary completion: May 9, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi66 open or runningphase 3since Sep 15, 2025Sep 15, 2025May 9, 2028phase 3 · NCT07184996
Teva Pharmaceutical Industriesits history only31 open or runningphase 2since Aug 24, 2020Aug 24, 2020none ahead
  • Named in Sanofi’s own pipeline as duvakitug, phase 3, as of Sep 30, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • Co-developmentSanofi develops it with Teva, Teva leads sales in Europe and Israel, Sanofi in North America, Japan and elsewhere.Announced Oct 4, 2023 · Source: Sanofi, Oct 4, 2023

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2023Named duvakitugINNProposed as its International Nonproprietary Name in WHO's List 128 · before, TEV-48574
  2. Oct 4, 2023Sanofi develops it with TevaCo-developmentTeva leads sales in Europe and Israel, Sanofi in North America, Japan and elsewhere · announced · Sanofi
  3. Sep 15, 2025First studies: 4 phase 3 studiesFirst studyNCT07185009, NCT07184996, NCT07184944 and 1 more
  4. Sep 4, 2026Phase 2 study in HidradenitisNCT07812116 · 156 planned · United States, Canada
  5. Nov 2, 2026Phase 1 study in Colitis, UlcerativeNCT07923383 · 25 planned

Ahead

  1. May 9, 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT07184996
  2. Jun 16, 2028Primary completion: phase 2 study in HidradenitisNCT07812116
  3. Aug 8, 2028Primary completion: phase 1 study in Colitis, UlcerativeNCT07923383
  4. Sep 21, 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT07185009

TargetBeta

“TL1A mAb”the company's pipeline, read by Claude · source

Other programs on TNFSF15

ProgramCompanyFurthest phaseStudies
PF-07261271Pfizerphase 11

Studies

All 6 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923383Colitis, Ulcerative1Not yet recruitingAug 8, 202825
NCT07812116Hidradenitis · United States, Canada2RecruitingJun 16, 2028156
NCT07185009Colitis, Ulcerative · United States, Argentina, Australia and more3RecruitingSep 21, 2028751
NCT07184996Colitis, Ulcerative · United States, Argentina, Australia and more3RecruitingMay 9, 2028980
NCT07184944Crohn Disease · United States, Australia, Austria and more3RecruitingAug 13, 2029751
NCT07184931Crohn Disease · United States, Argentina, Australia and more3RecruitingMay 14, 2029980

How it is read

Names in the registry

  • “Duvakitug”, 6 entries
  • “TEV-48574”, 2 entries
  • “TEV-48574 Dose Regimen A”, 1 entry
  • “TEV-48574 Dose Regiment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.